ASX - By Stock
|
SPL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
chrisnj
|
18 |
2.0K |
0 |
15:22 |
15:22 |
ASX - By Stock
|
18
|
2.0K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
chrisnj
|
18 |
2.0K |
2 |
10:35 |
10:35 |
ASX - By Stock
|
18
|
2.0K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
ASCO Presentations 2024
|
|
chrisnj
|
28 |
4.9K |
1 |
08:18 |
08:18 |
ASX - By Stock
|
28
|
4.9K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
ASCO Presentations 2024
|
|
chrisnj
|
28 |
4.9K |
2 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
28
|
4.9K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
ASCO Presentations 2024
|
|
chrisnj
|
28 |
4.9K |
4 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
28
|
4.9K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Could this happen to Viraleze with marketing approval
|
|
chrisnj
|
29 |
5.2K |
2 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
29
|
5.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Could this happen to Viraleze with marketing approval
|
|
chrisnj
|
29 |
5.2K |
2 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
29
|
5.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change in Director's Interest Notice - R Thomas
|
|
chrisnj
|
9 |
2.0K |
2 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
9
|
2.0K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Why no SPL announcement on TGA decison
|
|
chrisnj
|
13 |
2.1K |
1 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
13
|
2.1K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change in Director's Interest Notice - R Thomas
|
|
chrisnj
|
22 |
4.0K |
2 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
22
|
4.0K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change in Director's Interest Notice - R Thomas
|
|
chrisnj
|
22 |
4.0K |
3 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
22
|
4.0K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics
|
|
chrisnj
|
148 |
27K |
7 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
148
|
27K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
New xxsbiz interview on Starpharma/Medicxi $38 million deal
|
|
chrisnj
|
13 |
1.9K |
1 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
13
|
1.9K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
New xxsbiz interview on Starpharma/Medicxi $38 million deal
|
|
chrisnj
|
13 |
1.9K |
2 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
13
|
1.9K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics
|
|
chrisnj
|
148 |
27K |
5 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
148
|
27K
|
5
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics
|
|
chrisnj
|
148 |
27K |
3 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
148
|
27K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics
|
|
chrisnj
|
148 |
27K |
1 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
148
|
27K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Interim decision to amend the Poison Standard for astodrimer sodium
|
|
chrisnj
|
32 |
7.4K |
3 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
32
|
7.4K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Covid-19 is not over by a long shot ladies and gentlemen
|
|
chrisnj
|
102 |
21K |
2 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
102
|
21K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Starpharma's new website
|
|
chrisnj
|
5 |
1.0K |
6 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
5
|
1.0K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Starpharma's website has been updated
|
|
chrisnj
|
23 |
5.3K |
3 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
23
|
5.3K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
The blackout period remains in place
|
|
chrisnj
|
18 |
3.2K |
1 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
18
|
3.2K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
My pharmacist remains convinced
|
|
chrisnj
|
5 |
1.1K |
3 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
5
|
1.1K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: S&P DJI Announces March 2024 Quarterly Rebalance
|
|
chrisnj
|
27 |
6.2K |
2 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
27
|
6.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Has the seling dried up
|
|
chrisnj
|
72 |
13K |
1 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
72
|
13K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Half Yearly Report and Accounts
|
|
chrisnj
|
11 |
2.8K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
11
|
2.8K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Has the seling dried up
|
|
chrisnj
|
72 |
13K |
2 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
72
|
13K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Letter from Cheryl..
|
|
chrisnj
|
72 |
16K |
2 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
72
|
16K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Letter from Cheryl..
|
|
chrisnj
|
72 |
16K |
2 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
72
|
16K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VivaGel BV US FDA Appeal Outcome
|
|
chrisnj
|
60 |
13K |
2 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
60
|
13K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VivaGel BV US FDA Appeal Outcome
|
|
chrisnj
|
60 |
13K |
2 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
60
|
13K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VivaGel BV US FDA Appeal Outcome
|
|
chrisnj
|
60 |
13K |
1 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
60
|
13K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VivaGel BV US FDA Appeal Outcome
|
|
chrisnj
|
60 |
13K |
8 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
60
|
13K
|
8
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VivaGel BV US FDA Appeal Outcome
|
|
chrisnj
|
60 |
13K |
8 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
60
|
13K
|
8
|
|
ASX - By Stock
|
SPL |
Re:
Covid-19 is not over by a long shot ladies and gentlemen
|
|
chrisnj
|
102 |
21K |
6 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
102
|
21K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VivaGel BV US FDA Appeal Outcome
|
|
chrisnj
|
60 |
13K |
4 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
60
|
13K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Letter from Cheryl..
|
|
chrisnj
|
72 |
16K |
1 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
72
|
16K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Covid-19 is not over by a long shot ladies and gentlemen
|
|
chrisnj
|
102 |
21K |
2 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
102
|
21K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Mirrabooka creeps up the list of top 20 holders in Starpharma
|
|
chrisnj
|
42 |
12K |
2 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
42
|
12K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Covid-19 is not over by a long shot ladies and gentlemen
|
|
chrisnj
|
102 |
21K |
4 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
102
|
21K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Covid-19 is not over by a long shot ladies and gentlemen
|
|
chrisnj
|
102 |
21K |
4 |
11/02/24 |
11/02/24 |
ASX - By Stock
|
102
|
21K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Covid-19 is not over by a long shot ladies and gentlemen
|
|
chrisnj
|
102 |
21K |
7 |
10/02/24 |
10/02/24 |
ASX - By Stock
|
102
|
21K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
The comical commercialisation history of VivaGel BV
|
|
chrisnj
|
12 |
2.9K |
3 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
12
|
2.9K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Top Key Players in the Bacterial Vaginosis Drug Market
|
|
chrisnj
|
6 |
1.2K |
4 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
6
|
1.2K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
REBIRTH OR REINVENTION OF STARPHARMA
|
|
chrisnj
|
38 |
9.2K |
2 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
38
|
9.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
VIRALEZE™ nasal spray a blow for covid
|
|
chrisnj
|
37 |
6.1K |
2 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
37
|
6.1K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Viraleze shows antiviral efficacy in COVID-19 patients
|
|
chrisnj
|
74 |
14K |
3 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
74
|
14K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Viraleze shows antiviral efficacy in COVID-19 patients
|
|
chrisnj
|
74 |
14K |
3 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
74
|
14K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Viraleze shows antiviral efficacy in COVID-19 patients
|
|
chrisnj
|
74 |
14K |
4 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
74
|
14K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Viraleze reply Investor relations
|
|
chrisnj
|
41 |
8.7K |
1 |
27/01/24 |
27/01/24 |
ASX - By Stock
|
41
|
8.7K
|
1
|
|